Attend the FierceBiotech Executive Breakfast at JPM
Join us on January 14th at the Fairmont San Francisco. Register today.
All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.
Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.
Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.